Lilly appeals retatrutide classification ruling in case that could impact compounders / Endpoints
Alexis Kramer / endpoints - Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice ...
#obesity #healthcare #pharmaceuticals #elililly #weightloss #publichealth #drugdevelopment #fda #digitalhealth
Saturday, February 14, 2026, 12:21 pm / permalink 19191 / 15 stories in 24 days
Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B / MedCity
Frank Vinluan / medcitynews - Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by …
#healthcare #pharmaceuticals #elililly #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment
Saturday, February 14, 2026, 3:21 am / permalink 19178 / 9 stories in 25 days